The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Texas MPN Workshop 2021 | Myelofibrosis: updates on JAK inhibitors
Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, explores the next generation JAK inhibitors, momelotinib and pacritinib, which have been receiving increasing attention for the treatment of myelofibrosis in the past decade. Dr Bose discusses the niche patient sub-group characterized by a cytopenic phenotype and those with anemia which may benefit from such agents, highlighting the MOMENTUM trial (NCT04173494) which is comparing momelotinib to danazol for patients previously treated with a JAK inhibitor. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
Disclosures
Prithviraj Bose, MBBS, has received honoraria from Incyte, Celgene, BMS, CTI BioPharma, Sierra Oncology, Novartis, Blueprint Medicines and Kartos; and has received research support from Incyte, Celgene, BMS, CTI BioPharma, Constellation, Kartos, Blueprint Medicines, Astellas, Pfizer, Promedior and NS Pharma.
